X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Update

X4 Pharmaceuticals, Inc. (NASDAQ:XFORGet Free Report) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 9,480,000 shares, a decrease of 14.3% from the February 13th total of 11,060,000 shares. Approximately 5.7% of the company’s stock are sold short. Based on an average daily volume of 4,100,000 shares, the short-interest ratio is currently 2.3 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a research report on Friday, February 7th.

Check Out Our Latest Analysis on X4 Pharmaceuticals

Insider Buying and Selling

In other news, CFO Adam S. Mostafa sold 74,773 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $33,647.85. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Paula Ragan sold 76,473 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. This represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 202,663 shares of company stock valued at $91,198 over the last ninety days. Company insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. Verition Fund Management LLC purchased a new stake in shares of X4 Pharmaceuticals in the 3rd quarter worth $30,000. Cantor Fitzgerald L. P. purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth $30,000. Atria Wealth Solutions Inc. purchased a new stake in shares of X4 Pharmaceuticals in the 4th quarter worth $44,000. Wells Fargo & Company MN lifted its holdings in shares of X4 Pharmaceuticals by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 78,518 shares of the company’s stock worth $58,000 after buying an additional 26,763 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% in the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after buying an additional 22,485 shares during the period. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

X4 Pharmaceuticals Price Performance

XFOR opened at $0.29 on Wednesday. The business has a fifty day moving average of $0.48 and a 200 day moving average of $0.54. X4 Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $1.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. The stock has a market cap of $50.24 million, a P/E ratio of -3.27 and a beta of 0.39.

About X4 Pharmaceuticals

(Get Free Report)

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.

Featured Stories

Receive News & Ratings for X4 Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for X4 Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.